Korea's Green Cross in Talks with MNCs Over A/H1N1 Vaccine Adjuvants
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Amid rising concerns that the government may have to import substantial doses of an A/H1N1 flu vaccine soon from other countries, including China, South Korean vaccine maker Green Cross said it is currently in talks with multinational companies to buy the adjuvants used in production of the flu vaccine
You may also be interested in...
Korean Govt to Temporarily Exempt Tamiflu, Relenza from Tariffs; Green Cross Begins H1N1 Clinical Trials
SEOUL - The Korean government will temporarily exempt Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) from a tariff and a local value-added tax until the end of next year as part of an effort to help local A/H1N1 flu patients get fast and easy access to treatments at lower costs
Korean Govt to Temporarily Exempt Tamiflu, Relenza from Tariffs; Green Cross Begins H1N1 Clinical Trials
SEOUL - The Korean government will temporarily exempt Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) from a tariff and a local value-added tax until the end of next year as part of an effort to help local A/H1N1 flu patients get fast and easy access to treatments at lower costs
GSK To Supply Korea With 3 Million Doses of A/H1N1 Flu Vaccine By Year End
SEOUL - As part of its bid to better tackle spreading A/H1N1 flu infections, South Korea's Ministry for Health, Welfare and Family Affairs has asked GlaxoSmithKline to supply three million doses of its A/H1N1 flu vaccine within the year, rather than next year as originally planned